Query：
学者姓名：邵敬伟
Refining：
Year
Type
Indexed by
Source
Complex
Former Name
Co-
Language
Clean All
Abstract ：
Liver cancer, which is well-known to us as one of human most prevalent malignancies across the globe, poses a significant risk to live condition and life safety of individuals in every region of the planet. It has been shown that immune checkpoint treatment may enhance survival benefits and make a significant contribution to patient prognosis, which makes it a promising and popular therapeutic option for treating liver cancer at the current time. However, there are only a very few numbers of patients who can benefit from the treatment and there also exist adverse events such as toxic effects and so on, which is still required further research and discussion. Fortunately, the clustered regularly interspaced short palindromic repeat/CRISPR-associated nuclease 9 (CRISPR/Cas9) provides a potential strategy for immunotherapy and immune checkpoint therapy of liver cancer. In this review, we focus on elucidating the fundamentals of the recently developed CRISPR/Cas9 technology as well as the present-day landscape of immune checkpoint treatment which pertains to liver cancer. What’s more, we aim to explore the molecular mechanism of immune checkpoint treatment in liver cancer based on CRISPR/Cas9 technology. At last, its encouraging and powerful potential in the future application of the clinic is discussed, along with the issues that already exist and the difficulties that must be overcome. To sum up, our ultimate goal is to create a fresh knowledge that we can utilize this new CRISPR/Cas9 technology for the current popular immune checkpoint therapy to overcome the treatment issues of liver cancer. © 2024 IOP Publishing Ltd.
Keyword ：
CRISPR/Cas9 CRISPR/Cas9 immune checkpoint immune checkpoint immunotherapy immunotherapy liver cancer liver cancer
Cite：
Copy from the list or Export to your reference management。
| GB/T 7714 | Tong, L.-W. , Hu, Y.-S. , Yu, S.-J. et al. Current application and future perspective of CRISPR/cas9 gene editing system mediated immune checkpoint for liver cancer treatment [J]. | Nanotechnology , 2024 , 35 (40) . |
| MLA | Tong, L.-W. et al. "Current application and future perspective of CRISPR/cas9 gene editing system mediated immune checkpoint for liver cancer treatment" . | Nanotechnology 35 . 40 (2024) . |
| APA | Tong, L.-W. , Hu, Y.-S. , Yu, S.-J. , Li, C.-L. , Shao, J.-W. . Current application and future perspective of CRISPR/cas9 gene editing system mediated immune checkpoint for liver cancer treatment . | Nanotechnology , 2024 , 35 (40) . |
| Export to | NoteExpress RIS BibTex |
Version ：
Abstract ：
Both ursolic acid (UA) and sorafenib (Sora) have been generally utilized in cancer treatment, and the combination of the two has also shown a good anti-tumor effect. However, single-agent therapy for Hepatocellular carcinoma (HCC) has the disadvantages of multi-drug resistance, poor water solubility and low bioavailability, and the application of traditional nanocarrier materials is limited due to their low drug loading and low carrierrelated toxicity. Therefore, we prepared US NPs with different proportions of UA and Sora by solvent exchange method for achieving synergistic HCC therapy. US NPs had suitable particle size, good dispersibility and storage stability, which synergistically inhibited the proliferation of HepG2 cells, SMMC7721 cells and H22 cells. In addition, we also proved that US NPs were able to suppress the migration of HepG2 cells and SMMC7721 cells and reduce the adhesion ability and colony formation ability of these cells. According to the results, US NPs could degrade the membrane potential of mitochondrial, participate in cell apoptosis, and synergistically induce autophagy. Collectively, the carrier-free US NPs provide new strategies for HCC treatment and new ideas for the development of novel nano-drug delivery systems containing UA and Sora.
Keyword ：
Co-assembly Co-assembly Sorafenib Sorafenib Synergistic therapy Synergistic therapy Ursolic acid Ursolic acid
Cite：
Copy from the list or Export to your reference management。
| GB/T 7714 | Tong, Ling-Wu , Le, Jing-Qing , Song, Xun-Huan et al. Synergistic anti-tumor effect of dual drug co-assembled nanoparticles based on ursolic acid and sorafenib [J]. | COLLOIDS AND SURFACES B-BIOINTERFACES , 2024 , 234 . |
| MLA | Tong, Ling-Wu et al. "Synergistic anti-tumor effect of dual drug co-assembled nanoparticles based on ursolic acid and sorafenib" . | COLLOIDS AND SURFACES B-BIOINTERFACES 234 (2024) . |
| APA | Tong, Ling-Wu , Le, Jing-Qing , Song, Xun-Huan , Li, Cheng-Lei , Yu, Shi-Jing , Lin, Ying-Qi et al. Synergistic anti-tumor effect of dual drug co-assembled nanoparticles based on ursolic acid and sorafenib . | COLLOIDS AND SURFACES B-BIOINTERFACES , 2024 , 234 . |
| Export to | NoteExpress RIS BibTex |
Version ：
Abstract ：
The existing therapies for cancer are not remote satisfactory due to drug-resistance in tumors that are malignant. There is a pressing necessity to take a step forward to develop innovative therapies that can complement current ones. Multiple investigations have demonstrated that ferroptosis therapy, a non-apoptotic modality of programmed cell death, has tremendous potential in face of multiple crucial events, such as drug resistance and toxicity in aggressive malignancies. Recently, ferroptosis at the crosswalk of chemotherapy, materials science, immunotherapy, tumor microenvironment, and bionanotechnology has been presented to elucidate its therapeutic feasibility. Given the burgeoning progression of ferroptosis-based nanomedicine, the newest advancements in this field at the confluence of ferroptosis-inducers, nanotherapeutics, along with tumor microenvironment are given an overview. Here, the signaling pathways of ferroptosis-related were first talked about briefly. The emphasis discussion was placed on the pharmacological mechanisms and the nanodrugs design of ferroptosis inducing agents based on multiple distinct metabolism pathways. Additionally, a comprehensive overview of the action mechanisms by which the tumor microenvironment influences ferroptosis was elaborately descripted. Finally, some limitations of current researches and future research directions were also deliberately discussed to provide details about therapeutic avenues for ferroptosis-related diseases along with the design of anti-drugs.
Keyword ：
Ferroptosis Ferroptosis Nanodrug design Nanodrug design Pathway Pathway Pharmacological mechanism Pharmacological mechanism Tumor microenvironment Tumor microenvironment
Cite：
Copy from the list or Export to your reference management。
| GB/T 7714 | Yu, Shijing , Tong, Lingwu , Shen, Jiangwen et al. Recent research progress based on ferroptosis-related signaling pathways and the tumor microenvironment on it effects [J]. | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , 2024 , 269 . |
| MLA | Yu, Shijing et al. "Recent research progress based on ferroptosis-related signaling pathways and the tumor microenvironment on it effects" . | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 269 (2024) . |
| APA | Yu, Shijing , Tong, Lingwu , Shen, Jiangwen , Li, Chenglei , Hu, Yongshan , Feng, Keke et al. Recent research progress based on ferroptosis-related signaling pathways and the tumor microenvironment on it effects . | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , 2024 , 269 . |
| Export to | NoteExpress RIS BibTex |
Version ：
Abstract ：
The heterogeneity of hepatocellular carcinoma (HCC) and the complexity of the tumor microenvironment (TME) pose challenges to efficient drug delivery and the antitumor efficacy of combined or synergistic therapies. Herein, a metal-coordinated carrier-free nanodrug (named as USFe3+ LA NPs) was developed for ferroptosis-mediated multimodal synergistic anti-HCC. Natural product ursolic acid (UA) was incorporated to enhance the sensitivity of tumor cells to sorafenib (SRF). Surface decoration of cell penetration peptide and epithelial cell adhesion molecule aptamer facilitated the uptake of USFe3+ LA NPs by HepG2 cells. Meanwhile, Fe3+ ions could react with intracellular hydrogen peroxide, generating toxic hydroxyl radical (& sdot;OH) for chemodynamical therapy (CDT) and amplified ferroptosis by cystine/glutamate antiporter system (System Xc ), which promoted the consumption of glutathione (GSH) and inhibited the expression of glutathione peroxidase 4 (GPX4). Notably, these all-in-one nanodrugs could inhibit tumor metastasis and induced immunogenic cell death (ICD). Last but not least, the nanodrugs demonstrated favorable biocompatibility, augmenting the immune response against the programmed death-ligand 1 (PD-L1) by increasing cytotoxic T cell infiltration. In vivo studies revealed significant suppression of tumor growth and distant metastasis. Overall, our work introduced a novel strategy for applications of metalcoordinated co-assembled carrier-free nano-delivery system in HCC combination therapy, especially in the realms of cancer metastasis prevention and immunotherapy.
Keyword ：
Chemodynamical therapy Chemodynamical therapy Ferroptosis Ferroptosis Immunotherapy Immunotherapy Metal -coordinated nanoplatform Metal -coordinated nanoplatform Synergistic chemotherapy Synergistic chemotherapy
Cite：
Copy from the list or Export to your reference management。
| GB/T 7714 | Zhao, Rui-Rui , Wu, Ju-Hong , Li, Jin -Yu et al. Multifunctional metal-coordinated Co-assembled carrier-free nanoplatform based on dual-drugs for ferroptosis-mediated cocktail therapy of hepatocellular carcinoma growth and metastasis [J]. | JOURNAL OF COLLOID AND INTERFACE SCIENCE , 2024 , 660 : 257-276 . |
| MLA | Zhao, Rui-Rui et al. "Multifunctional metal-coordinated Co-assembled carrier-free nanoplatform based on dual-drugs for ferroptosis-mediated cocktail therapy of hepatocellular carcinoma growth and metastasis" . | JOURNAL OF COLLOID AND INTERFACE SCIENCE 660 (2024) : 257-276 . |
| APA | Zhao, Rui-Rui , Wu, Ju-Hong , Li, Jin -Yu , Lu, Yu-sheng , Shao, Jing -Wei . Multifunctional metal-coordinated Co-assembled carrier-free nanoplatform based on dual-drugs for ferroptosis-mediated cocktail therapy of hepatocellular carcinoma growth and metastasis . | JOURNAL OF COLLOID AND INTERFACE SCIENCE , 2024 , 660 , 257-276 . |
| Export to | NoteExpress RIS BibTex |
Version ：
Abstract ：
Ferroptosis, an emerging cell death mode discovered in recent decades, is characterized by lipid peroxidation during cell death, usually manifested as iron accumulation. However, the forthright delivery of iron species will cause adverse detrimental effects such as anaphylactic reactions in routine tissues. So far, studies on cellular ferroptosis by employing bio-derived nanomaterials have rarely been acquired. Herein, we reported carbon dots (CDs)-based biocompatible enzymes with negligible toxicity from a representative hepatoprotective triterpenoid natural product ursolic acid (UA) with acknowledged antitumor activity. We observed that CDs presented distinct GSH oxidase-like characteristics and then contributed ferroptosis of carcinoma cells by interfering with the GPX4-catalyzed lipid repair system. After the CDs were assembled with UA, the obtained denoted as UCDs integrated multi-model therapy into one, resulting in enhanced therapeutic efficacy, reduced adverse effects, and optimized clinical outcomes. In vivo, the UCDs hysterically inhibited tumor growth in hepatoma H22-bearing mice with inconsequential toxicity. Exceptionally, UCDs enlisted a large number of tumor-infiltrating immune cells, including T cells, NK cells, and macrophages in H22 tumor-bearing mice, consequently transforming "cold" into "hot" tumors to activate systemic anti-tumor immune responses. Meanwhile, UCDs could also awfully suppress the H22-LUC tumor growth in orthotopic xenograft mouse models. Collectively, our research commends that the drug delivery systems based on natural-products-derived CDs can function as biocompatible enzymes for antitumor treatment and may facilitate the advancement of nanotechnology-based immunotherapeutics. It is extremely anticipated that such ferroptosis-like designing in nano-catalytic medicine would be favorable for future development in cancer-therapeutic regimens.
Keyword ：
Ferroptosis Ferroptosis Hepatocellular carcinoma Hepatocellular carcinoma Nanozyme Nanozyme Tumor immune microenvironment Tumor immune microenvironment
Cite：
Copy from the list or Export to your reference management。
| GB/T 7714 | Lai, Chun-Mei , Xu, Jia , Zhang, Bing -Chen et al. A natural product-derived nanozyme regulator induced chemo-ferroptosis dual therapy in remodeling of the tumor immune microenvironment of hepatocellular carcinoma [J]. | CHEMICAL ENGINEERING JOURNAL , 2024 , 482 . |
| MLA | Lai, Chun-Mei et al. "A natural product-derived nanozyme regulator induced chemo-ferroptosis dual therapy in remodeling of the tumor immune microenvironment of hepatocellular carcinoma" . | CHEMICAL ENGINEERING JOURNAL 482 (2024) . |
| APA | Lai, Chun-Mei , Xu, Jia , Zhang, Bing -Chen , He, Shao-Hua , Shao, Jing-Wei . A natural product-derived nanozyme regulator induced chemo-ferroptosis dual therapy in remodeling of the tumor immune microenvironment of hepatocellular carcinoma . | CHEMICAL ENGINEERING JOURNAL , 2024 , 482 . |
| Export to | NoteExpress RIS BibTex |
Version ：
Abstract ：
本发明属于生物医药技术领域，具体涉及一种基于双药共组装的兼具光‑化疗的仿生纳米粒的制备及其应用。所述仿生纳米粒由外壳和所述外壳包覆的纳米内核组成，所述外壳为HepG2细胞膜，所述纳米内核由抗肿瘤疏水性药物索拉非尼、抗心血管疾病疏水性药物普萘洛尔及光敏剂吲哚菁绿共组装形成。所仿生纳米粒能通过细胞膜同源识别作用在肝癌部位特异性积蓄，并在808 nm激光的照射下精准高效释放药物，实现多药‑多疗法联合抗肝癌作用，对肝癌的生长具有显著的抑制作用，在制备抗肝癌药物中具有广大的应用前景。
Cite：
Copy from the list or Export to your reference management。
| GB/T 7714 | 邵敬伟 , 罗邦悦 , 李林燕 . 一种基于双药共组装的兼具光-化疗的仿生纳米粒的制备及其应用 : CN202210289753.3[P]. | 2022-03-23 00:00:00 . |
| MLA | 邵敬伟 et al. "一种基于双药共组装的兼具光-化疗的仿生纳米粒的制备及其应用" : CN202210289753.3. | 2022-03-23 00:00:00 . |
| APA | 邵敬伟 , 罗邦悦 , 李林燕 . 一种基于双药共组装的兼具光-化疗的仿生纳米粒的制备及其应用 : CN202210289753.3. | 2022-03-23 00:00:00 . |
| Export to | NoteExpress RIS BibTex |
Version ：
Abstract ：
本发明提供了一种无载体双药自组装纳米粒的制备及用途。本发明利用溶剂交换法将化疗药物索拉非尼与天然产物熊果酸分子通过π‑烷基键、烷基键、氢键自组装形成纳米粒，然后将吲哚菁绿物理吸附到纳米粒中，并在纳米粒表面修饰核酸适配体及细胞穿膜肽，从而制得所述无载体双药自组装纳米粒。本发明有效避免了传统高分子或无机载体的引入以及共修饰带来的潜在毒性，为纳米技术应用于癌症治疗领域提供了新途径。
Cite：
Copy from the list or Export to your reference management。
| GB/T 7714 | 邵敬伟 , 乐景青 , 杨芳 . 一种无载体双药自组装纳米粒的制备及用途 : CN202111598274.1[P]. | 2021-12-24 00:00:00 . |
| MLA | 邵敬伟 et al. "一种无载体双药自组装纳米粒的制备及用途" : CN202111598274.1. | 2021-12-24 00:00:00 . |
| APA | 邵敬伟 , 乐景青 , 杨芳 . 一种无载体双药自组装纳米粒的制备及用途 : CN202111598274.1. | 2021-12-24 00:00:00 . |
| Export to | NoteExpress RIS BibTex |
Version ：
Abstract ：
本发明属于生物医药技术领域，具体涉及一种基于金属‑有机共组装的无载体纳米药物及其制备与应用。本发明将疏水性天然产物熊果酸、疏水性抗癌药物索拉非尼以及铁离子通过一种绿色、简单的方法自组装成无载体纳米粒，不仅解决了纳米载体潜在的安全性问题，同时达到天然产物熊果酸与索拉非尼的协同抗肿瘤作用，铁离子的加入进一步提高索拉非尼的抗肝癌效果，具有较大的临床应用潜力。
Cite：
Copy from the list or Export to your reference management。
| GB/T 7714 | 邵敬伟 , 张文钟 , 赵瑞瑞 et al. 一种基于金属-有机共组装的无载体纳米药物及其制备与应用 : CN202111441191.1[P]. | 2021-11-30 00:00:00 . |
| MLA | 邵敬伟 et al. "一种基于金属-有机共组装的无载体纳米药物及其制备与应用" : CN202111441191.1. | 2021-11-30 00:00:00 . |
| APA | 邵敬伟 , 张文钟 , 赵瑞瑞 , 方伊凡 . 一种基于金属-有机共组装的无载体纳米药物及其制备与应用 : CN202111441191.1. | 2021-11-30 00:00:00 . |
| Export to | NoteExpress RIS BibTex |
Version ：
Abstract ：
本发明公开了一种基于血红蛋白的携氧增敏纳米药物的制备方法及应用。本发明首先分别将熊果酸、索拉非尼、吲哚菁绿溶于良性溶剂中，分别得到溶液A、溶液B和溶液C，将溶液A、溶液B和溶液C混合得到溶液D，再将适量溶液D滴入到二次蒸馏水中，随后超声处理，再用氮吹仪吹干良性溶剂，得到纳米药物‑1水溶液，最后将红细胞悬液和纳米药物‑1水溶液按照一定比例混合，过膜，即得到所述基于血红蛋白的携氧增敏纳米药物。本发明利用红细胞中血红蛋白的携氧‑释氧功能有效改善肿瘤乏氧环境，实现多重增敏作用，制备方法绿色、简单，结合血红蛋白携氧功能有效减小传统治疗手段的抗性，提高抗肿瘤作用，具有广阔的临床应用前景。
Cite：
Copy from the list or Export to your reference management。
| GB/T 7714 | 邵敬伟 , 杨芳 , 乐景青 . 一种基于血红蛋白的携氧增敏纳米药物的制备方法及应用 : CN202210165627.7[P]. | 2022-02-23 00:00:00 . |
| MLA | 邵敬伟 et al. "一种基于血红蛋白的携氧增敏纳米药物的制备方法及应用" : CN202210165627.7. | 2022-02-23 00:00:00 . |
| APA | 邵敬伟 , 杨芳 , 乐景青 . 一种基于血红蛋白的携氧增敏纳米药物的制备方法及应用 : CN202210165627.7. | 2022-02-23 00:00:00 . |
| Export to | NoteExpress RIS BibTex |
Version ：
Abstract ：
The in-depth intersection between nanoscience and oncology comes from the fact that nanomaterials are in a similar dimension to basic biomolecules. Drug delivery systems (DDSs), which are either targeted to a particular site or intended for the controlled release in a particular position, have been studied extensively at the nanoscale and are, by far, the most advanced technology in the area of nanoparticle applications. This, consequently lead to the improvement and development of convenient administration routes, lower toxicity, fewer side effects, and extended drug life cycle. Carbon nanomaterials (CNMs) with favorable size and unique fluorescence properties, which was considered an ideal candidate to transport or deliver therapeutic drugs to specific targets in a controlled manner. The development of DDSs based on them constitutes an interesting topic in highly effective and universal therapies to achieve better therapeutic outcomes and reduce the side effects of malignancies. In this review, the cutting-edge progress of CNMs in DDSs was comprehensively summarized. Additionally, the emphasis was placed on the applications of CNMs including fullerene, graphene, carbon nanotubes (CNTs), carbon dots (CDs), and nano-diamonds (NDs) in drug delivering. Further, we gave some insights into the future direction and foreseeable challenges of DDSs based on CNMs used in cancer therapy, which we hope these inspirations in DDSs associated with anti-cancer therapy will provide perspectives in designing new drugs for further tumor treatment.
Keyword ：
cancer treatment cancer treatment carbon dots carbon dots Carbon nanomaterials Carbon nanomaterials drug delivery drug delivery nano-diamonds nano-diamonds nanoscience nanoscience
Cite：
Copy from the list or Export to your reference management。
| GB/T 7714 | Lai, Chunmei , Li, Linyan , Luo, Bangyue et al. Current Advances and Prospects in Carbon Nanomaterials-based Drug Deliver Systems for Cancer Therapy [J]. | CURRENT MEDICINAL CHEMISTRY , 2023 , 30 (24) : 2710-2733 . |
| MLA | Lai, Chunmei et al. "Current Advances and Prospects in Carbon Nanomaterials-based Drug Deliver Systems for Cancer Therapy" . | CURRENT MEDICINAL CHEMISTRY 30 . 24 (2023) : 2710-2733 . |
| APA | Lai, Chunmei , Li, Linyan , Luo, Bangyue , Shen, Jiangwen , Shao, Jingwei . Current Advances and Prospects in Carbon Nanomaterials-based Drug Deliver Systems for Cancer Therapy . | CURRENT MEDICINAL CHEMISTRY , 2023 , 30 (24) , 2710-2733 . |
| Export to | NoteExpress RIS BibTex |
Version ：
Export
| Results： |
Selected to |
| Format： |
